ASX:VIT

VITURA

ASX ANNOUNCEMENT

Cortexa Advances Commercialisation of MDMA Supply in Australia

23 MARCH 2026

Melbourne-based Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4-methylenedioxymethamphetamine).

Cortexa is a 50/50 joint venture between Vitura Health (ASX: VIT) and PharmAla Biotech (CSE: MDMA). Following completion of the world's largest (and first Australian) GMP batch of MDMA capsules earlier this financial year, the Company has secured supply arrangements with authorised providers nationally to support clinical programs and patient treatment under Australia's regulated prescribing pathways.

Through Cortexa's market activities, most of the initial batch has now been committed contributing to a first batch sales value forecast to exceed AUD$1.0 million.

To support current and future requirements, PharmAla has initiated the production of a second GMP batch of a new 20mg dosage form (another Australian first), which is expected to be available to Cortexa's customers in the second quarter of calendar year 2026.

Vitura's Chief Revenue Officer, Ryan Tattle, commented "Cortexa's significant increase in its supply of MDMA confirms its confidence of the expected sizeable growth in the psychedelics market in Australia."

Cortexa's products are manufactured to support local clinical research and patient treatments by Authorised Psychiatrists under the Therapeutic Goods Administration's (TGA's) Authorised Prescriber Scheme. Since 1 July 2023, psychedelics have been available to be prescribed in Australia for the treatment of specific mental health conditions.

The company also confirms that the previously contracted three-year licence arrangement with joint venture partner PharmAla Biotech, which involved annual licence payments of $250,000 for manufacturing and intellectual property rights, concludes during the current financial year (FY2026). The completion of this arrangement continues to allow ongoing access to the relevant manufacturing processes and associated intellectual property exclusively provided for the Cortexa joint venture structure. Cortexa will continue to benefit from PharmAla's product development activity, as the Joint Venture has right of first refusal on any new innovations developed by PharmAla for the Australian market.

In parallel, developments in the Australian healthcare system continue to support the emerging psychedelic therapies sector, including reimbursement initiatives from organisations such as Medibank Private and treatment support programs through the Department of Veterans' Affairs.

Mr Tattle said the operational progress reflected the strength of Cortexa's commercial strategy and focus within Vitura.

"Cortexa provides Vitura with an important diversification of its revenue streams. The Cortexa team at Vitura are to be congratulated on furthering the commercial operations through its supply arrangements."

Cortexa expects these developments to underpin the joint venture's planned commercial growth outcomes for FY2026 and beyond.

ENDS

Authorised by

Authorised for release to the ASX by the Board of Vitura Health Limited.

Contact

Vitura Health Limited
Ryan Tattle
Chief Revenue Officer
1300 799 491
info@vitura.com.au

Media enquiries
Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.

About Vitura Health Limited (ASX: VIT)

- www.vitura.com.au
  Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:
- www.burleighheadscannabis.com
  Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.
- www.canview.com.au
  Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

  Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au
  The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.

- www.cortexa.com.au
  The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

- www.candor.com.au
  The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.

- www.releaf.com.au
  The Company owns a 50% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

- www.cdaclinics.com.au
  The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

- www.cannadoc.com.au
  The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.